
FibroGen FGEN
Annual report 2025
added 03-16-2026
FibroGen Gross Profit 2011-2026 | FGEN
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit FibroGen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 255 M | - | - | - | - | - | 102 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 255 M | 102 M | 179 M |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
180 M | - | 2.43 % | $ 254 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
5.52 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
5.51 M | - | 2.54 % | $ 160 B | ||
|
Midatech Pharma plc
MTP
|
-428 K | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 | - | -1.52 % | $ 24.7 M | ||
|
Acorda Therapeutics
ACOR
|
119 M | - | -24.86 % | $ 820 K | ||
|
DBV Technologies S.A.
DBVT
|
74 K | $ 20.52 | 0.79 % | $ 2.86 B | ||
|
Alterity Therapeutics Limited
ATHE
|
177 K | $ 3.72 | 3.24 % | $ 8.95 B | ||
|
Advaxis
ADXS
|
90 K | - | -9.65 % | $ 45.9 M | ||
|
Adverum Biotechnologies
ADVM
|
2.32 M | - | - | $ 86.2 M | ||
|
Aytu BioScience
AYTU
|
45.8 M | $ 2.57 | -3.48 % | $ 16.1 M | ||
|
Институт стволовых клеток человека
ISKJ
|
774 M | - | - | - | ||
|
Fennec Pharmaceuticals
FENC
|
20 M | $ 6.22 | -3.12 % | $ 178 M | ||
|
Aeterna Zentaris
AEZS
|
4.73 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
102 K | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
10 K | - | 1.93 % | $ 17.4 M | ||
|
Gilead Sciences
GILD
|
17.8 B | $ 138.79 | -0.96 % | $ 173 B | ||
|
Genmab A/S
GMAB
|
-182 M | $ 27.26 | -1.77 % | $ 17.2 B | ||
|
Grifols, S.A.
GRFS
|
2.79 B | $ 8.02 | -2.55 % | $ 6.83 B | ||
|
GT Biopharma
GTBP
|
27 K | $ 0.41 | -7.26 % | $ 2.26 M | ||
|
CureVac N.V.
CVAC
|
-10.6 M | - | - | $ 867 M | ||
|
Halozyme Therapeutics
HALO
|
150 M | $ 63.49 | 0.64 % | $ 7.61 B | ||
|
Coherus BioSciences
CHRS
|
339 M | $ 1.62 | -3.1 % | $ 190 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
195 M | $ 318.56 | -3.57 % | $ 41.7 B | ||
|
Harmony Biosciences Holdings
HRMY
|
670 M | $ 27.62 | -0.34 % | $ 1.59 B | ||
|
iBio
IBIO
|
909 K | $ 2.08 | 2.47 % | $ 21.8 M | ||
|
ImmuCell Corporation
ICCC
|
11.4 M | $ 6.54 | -1.06 % | $ 59 M | ||
|
InflaRx N.V.
IFRX
|
-7.24 M | $ 0.99 | 4.91 % | $ 152 M | ||
|
Immutep Limited
IMMP
|
1.87 M | $ 0.35 | -3.58 % | $ 1.08 B |